

ANSWERING REVIEWERS



December 23, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: #5744-Review-2nd-SN.doc).

Title: Hepatitis C virus NS5A inhibitors and drug resistance mutations

Authors: Shingo Nakamoto, Tatsuo Kanda, Shuang Wu, Hiroshi Shirasawa, Osamu Yokosuka

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 5744 **ID (00012386)**

The manuscript has been improved according to the reviewers' suggestions:

1 The format has been updated

2 Revisions have been made according to the suggestions of the reviewer

(1) The comment from reviewer 00013065

Response to your comment 1): "The English spelling and grammar needs attention at places and should be checked carefully."

Thank you for your valuable comment. We agree with you. In accordance with your suggestion, we asked a native English speaker to correct and improve our manuscript.

Response to your comment 2): "There are a huge number of references (up to 95). In my opinion that is not necessary, also not in a review article. The authors my focus on the "key" literature and references and reduce the number of the references dramatically."

Thank you for your valuable comment. We agree with you. In response to your suggestion, we reduced the number of references to 91.

Response to your comment 3): "A figure showing schematically the algorithm of current treatment options against HCV would be helpful."

Thank you for your valuable comment. We agree with you, and we have included a new Figure 3 in the revised manuscript.

Response to your comment 4): "A more precise conclusion including a clear statement of the authors what they personally recommend from the current status of anti-HCV treatment options will not leave the reader alone at the end with the data and findings described in their review article."

Thank you for your valuable comment. We agree with you. In response to your suggestion, we revised our manuscript as follows.

In the Conclusion section, page 12, lines 11 - 14, the new text reads as follows:

.....prevent the emergence of resistant variants. **An algorithm of the current treatment options for**

HCV genotypes 1 and 2 is shown in Figure 3. In the near future, HCV NS5A inhibitors will play a critical role in interferon-free regimens in HCV genotype 1 patients.

Response to your comment 5): "There are a great number of abbreviations in this review which are not well explained. A list will be helpful for the reader."

Thank you for your valuable comment. We agree with you. In accordance with your suggestion, we have added an abbreviations list after the keywords section.

(2) The comment from reviewer 01588404

Response to your comment: "The authors need to stress more on the safety profile and low concentrations required with NS5A inhibitors which make them attractive for use despite low genetic barrier. This should be clear in the abstract and introduction as this is the reason for using these drugs either with NS3A or NS5B inhibitors or with IFN, ribavirin. As the authors have pointed out the second gen inhibitors improve on the genetic barrier while maintaining potency."

Thank you for your valuable comment. We agree with you. We have revised our manuscript accordingly.

3 The references and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,



Tatsuo Kanda, M.D., Ph.D., Associate Professor,
Department of Gastroenterology and Nephrology, Chiba University,
Graduate School of Medicine, Chiba 260-8670, Japan.
Fax: +81-43-226-2088
E-mail: kandat-cib@umin.ac.jp

Format for ANSWERING REVIEWERS



October 25, 2013

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: ##5744Format for minireviews 中本 R.doc).

Title: Hepatitis C virus NS5A inhibitors and drug resistance mutations

Author: Shingo Nakamoto, Tatsuo Kanda, Shuang Wu, Hiroshi Shirasawa, Osamu Yokosuka

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 5744

The manuscript has been improved according to the suggestions of the reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewers

(1) The comment from reviewer **00158779**

Response to your comment: "Nakamoto and co-workers present a review focusing on HCV NS5A inhibitors and drug resistance. Recommendations. English language should be polished in some points. This very special and complicated matter needs a list of abbreviation."

Thank you for your valuable comment. We agree with you. According to your suggestion, we asked a native English speaker to correct and improve our manuscript.

Response to your comment: "Introduction: An additional figure1 depicting the whole HCV genome is recommended, then present figure 1 can be better allocated by the reader."

Thank you for your valuable comment. We agree with you. We revised Figure 1 accordingly.

Response to your comment: " Figure 2: The legend must be more informative; what does n=548 and (1 or <1) refer to? Additionally, the layout of this figure may be improved. Table 1: Legend must be more informative, explain significance of dose dilution."

Thank you. We agree with you. We revised Figure 2 and Table 1 legend accordingly.

(2) The comment from reviewer **00503546**

Response to your comment: Thank you for your encouraging comments.

(3) The comment from reviewer **00504040**

Response to your comment: "It is suitable to publish in this journal after major revision as the following indications: 1. many English sentences are not readable, and should be polished under the help of a English native speaker. E.g. "This review article describes and recommends that we learn that HCV NS5A inhibitors should be used in combination regimens potent enough to prevent the emergence of resistant variants."; "Sustained virological response, defined as undetectable HCV RNA at week 24 (SVR24) after

stopping the treatment, is achieved in approximately 50% and 80%, respectively, following the combination therapy with peginterferon plus ribavirin for 48 weeks in HCV genotype 1 and 24 weeks in HCV genotype 2[6-9].”.....”

Thank you for your valuable comment. We agree with you. According to your suggestion, we asked a native English speaker to check and improve our manuscript.

Response to your comment: “Too many references to be cited in this article.”

Thank you for your valuable comment. We agree with you. According to your suggestion, we deleted several references.


Response to your comment: “sub-title “EFFICACY OF DACLATASVIR (DCV) IN VITRO” is not matched its contents that meanly described drug resistant mutants , and is lack of efficacy information from clinical trial of Daclatasvir.”

Thank you. We agree with you. We revised our manuscript accordingly.

3 References and typesetting were corrected.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,



Tatsuo Kanda, M.D., Ph.D., Associate Professor,
Department of Gastroenterology and Nephrology, Chiba University,
Graduate School of Medicine, Chiba 260-8670, Japan.

Fax: +81-43-226-2088

E-mail: kandat-cib@umin.ac.jp